The most recent preliminary estimates of incidence rates and trends are for 2000-2017. Users should refer to the official rates for 1975-2018 in SEER*Explorer, which was released in April 2021.
Based on results from the February 2019 SEER submission of cases for 2017 rates and trends, the following figures and tables are presented. Caution is advised when interpreting these figures and tables, as these are preliminary results and are subject to change for 2017 with the addition of data from more recent case submissions.
Data are also available for download for use in your own software.
Preliminary 5-year Average Annual Percent Change (AAPC) Estimates
Based on Joinpoint Analyses 2000-2017
February 2019 SEER Submission, SEER 18 Registries
Preliminary 5-year AAPC Estimates
Male, All Races
Preliminary 5-year AAPC Estimates
Female, All Races
Preliminary 5-year AAPC Estimates
Male, White
Preliminary 5-year AAPC Estimates
Female, White
Preliminary 5-year AAPC Estimates
Male, Black
Preliminary 5-year AAPC Estimates
Female, Black
The graph above presents the Average Annual Percent Change (What is an AAPC?) for 2013-2017 based on the preliminary rates through 2017.
The Joinpoint analyses on the series allowed up to 3 Joinpoints in the trend.
The underlying rates in the analysis were adjusted for reporting delay in the registry.
* The AAPC is significantly different from zero (p<.05).
5-year Delay-Adjusted Ratesa
February 2019 SEER Submission (2000-2017), SEER 18 Registries
Cancer Site | Sex | Race | Delay-adjusted rates a 2013-2017 |
---|---|---|---|
All Sites | Male | All Races | 476.6 |
White | 484.6 | ||
Black | 528.7 | ||
Female | All Races | 416.0 | |
White | 431.9 | ||
Black | 407.4 | ||
All Sites (Ages 0-19) | Male | All Races | 19.3 |
White | 20.6 | ||
Black | 14.1 | ||
Female | All Races | 18.0 | |
White | 19.1 | ||
Black | 13.8 | ||
Brain and Other Nervous System | Male | All Races | 7.6 |
White | 8.3 | ||
Black | 4.7 | ||
Female | All Races | 5.4 | |
White | 6.0 | ||
Black | 3.5 | ||
Breast | Female | All Races | 127.3 |
White | 129.8 | ||
Black | 129.1 | ||
Cervix | Female | All Races | 7.5 |
White | 7.5 | ||
Black | 8.3 | ||
Colon and Rectum | Male | All Races | 44.1 |
White | 43.5 | ||
Black | 53.4 | ||
Female | All Races | 34.0 | |
White | 33.7 | ||
Black | 40.7 | ||
Corpus and Uterus NOS | Female | All Races | 26.8 |
White | 27.4 | ||
Black | 26.5 | ||
Esophagus | Male | All Races | 7.1 |
White | 7.6 | ||
Black | 6.1 | ||
Female | All Races | 1.7 | |
White | 1.7 | ||
Black | 2.1 | ||
Hodgkin Lymphoma | Male | All Races | 2.8 |
White | 3.0 | ||
Black | 3.0 | ||
Female | All Races | 2.2 | |
White | 2.4 | ||
Black | 2.2 | ||
Kidney and Renal Pelvis | Male | All Races | 22.5 |
White | 23.1 | ||
Black | 25.9 | ||
Female | All Races | 11.3 | |
White | 11.7 | ||
Black | 13.3 | ||
Larynx | Male | All Races | 4.9 |
White | 4.9 | ||
Black | 7.9 | ||
Female | All Races | 1.0 | |
White | 1.1 | ||
Black | 1.5 | ||
Leukemia | Male | All Races | 18.9 |
White | 20.4 | ||
Black | 14.9 | ||
Female | All Races | 11.5 | |
White | 12.3 | ||
Black | 9.7 | ||
Liver and Intrahepatic Bile Duct | Male | All Races | 14.1 |
White | 12.8 | ||
Black | 17.9 | ||
Female | All Races | 5.0 | |
White | 4.6 | ||
Black | 5.4 | ||
Lung and Bronchus | Male | All Races | 61.0 |
White | 61.2 | ||
Black | 77.0 | ||
Female | All Races | 47.1 | |
White | 49.7 | ||
Black | 47.0 | ||
Melanoma of the Skin | Male | All Races | 30.8 |
White | 36.9 | ||
Black | 1.2 | ||
Female | All Races | 18.6 | |
White | 22.9 | ||
Black | 0.9 | ||
Myeloma | Male | All Races | 9.0 |
White | 8.5 | ||
Black | 17.6 | ||
Female | All Races | 5.8 | |
White | 5.1 | ||
Black | 12.9 | ||
Non-Hodgkin Lymphoma | Male | All Races | 23.8 |
White | 25.1 | ||
Black | 18.0 | ||
Female | All Races | 16.1 | |
White | 17.0 | ||
Black | 12.5 | ||
Oral Cavity and Pharynx | Male | All Races | 17.5 |
White | 18.5 | ||
Black | 14.1 | ||
Female | All Races | 6.4 | |
White | 6.7 | ||
Black | 5.1 | ||
Ovary | Female | All Races | 11.2 |
White | 11.7 | ||
Black | 9.3 | ||
Pancreas | Male | All Races | 14.7 |
White | 14.8 | ||
Black | 17.6 | ||
Female | All Races | 11.5 | |
White | 11.4 | ||
Black | 14.6 | ||
Prostate | Male | All Races | 108.4 |
White | 102.7 | ||
Black | 177.0 | ||
Stomach | Male | All Races | 9.6 |
White | 8.7 | ||
Black | 13.5 | ||
Female | All Races | 5.2 | |
White | 4.6 | ||
Black | 7.2 | ||
Testis | Male | All Races | 5.9 |
White | 7.1 | ||
Black | 1.6 | ||
Thyroid | Male | All Races | 7.4 |
White | 8.0 | ||
Black | 3.9 | ||
Female | All Races | 21.5 | |
White | 22.9 | ||
Black | 13.5 | ||
Urinary Bladder | Male | All Races | 33.6 |
White | 37.0 | ||
Black | 20.5 | ||
Female | All Races | 8.2 | |
White | 8.9 | ||
Black | 6.9 | ||
aRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130). |
Joinpoint Trend Analyses
November 2018 SEER Submission (2000-2016) and
February 2019 SEER Submission (2000-2017)
SEER 18 Registries
The numbers presented in the table below represent the Annual Percent Change (APC) in incidence rates. An APC is estimated based on a model that fits a linear trend to the log of the annual incidence rate. This model also estimates whether a trend changes significantly in direction or magnitude and, if it does, determines when the change(s) occurs. If a trend does not change over time, then there is only one estimate provided for the entire time period. If there is one or more points where a trend changes, the table shows each APC estimate and the years for which each estimate applies. The analyses allowed up to 3 changes (joinpoints) to occur in the trend.For more information about the model used to estimate these trends, visit Joinpoint Trend Analysis Software.
Cancer Site | Sex | Race | November 2018 Submission Joinpoint Trends |
February 2019 Submission Preliminary Joinpoint Trends |
||
---|---|---|---|---|---|---|
Annual Percent Change, 2000-2016 APC (Year Range) |
Average Annual Percent Change, 2012-2016 |
Annual Percent Change, 2000-2017 APC (Year Range) |
Average Annual Percent Change, 2013-2017 |
|||
All Sites | Male | All Races | -0.7* (2000-08) -2.0* (2008-16) | -2.0* | -0.8* (2000-08) -1.8* (2008-17) | -1.8* |
White | -0.6* (2000-08) -1.9* (2008-16) | -1.9* | -0.7* (2000-08) -1.8* (2008-17) | -1.8* | ||
Black | -1.8* (2000-06) -0.2 (2006-09) -3.7* (2009-14) -0.2 (2014-16) | -1.9* | -1.9* (2000-17) | -1.9* | ||
Female | All Races | -0.1 (2000-16) | -0.1 | -0.8* (2000-05) 0.9 (2005-08) -0.1 (2008-17) | -0.1 | |
White | 0.0 (2000-16) | 0.0 | -1.1 (2000-03) 0.1 (2003-17) | 0.1 | ||
Black | 0.1 (2000-16) | 0.1 | 0.1 (2000-17) | 0.1 | ||
All Sites (Ages 0-19) | Male | All Races | 0.7* (2000-16) | 0.7* | 0.7* (2000-17) | 0.7* |
White | 0.6* (2000-16) | 0.6* | 0.6* (2000-17) | 0.6* | ||
Black | 1.3* (2000-16) | 1.3* | 1.1* (2000-17) | 1.1* | ||
Female | All Races | 1.2* (2000-16) | 1.2* | 1.1* (2000-17) | 1.1* | |
White | 1.1* (2000-16) | 1.1* | 1.1* (2000-17) | 1.1* | ||
Black | 1.4* (2000-16) | 1.4* | 1.4* (2000-17) | 1.4* | ||
Brain and Other Nervous System | Male | All Races | -0.3* (2000-16) | -0.3* | -0.2* (2000-17) | -0.2* |
White | -0.2 (2000-16) | -0.2 | -0.2 (2000-17) | -0.2 | ||
Black | -0.2 (2000-16) | -0.2 | -0.1 (2000-17) | -0.1 | ||
Female | All Races | -0.3 (2000-16) | -0.3 | -0.3* (2000-17) | -0.3* | |
White | -0.2 (2000-16) | -0.2 | -0.1 (2000-17) | -0.1 | ||
Black | -0.6 (2000-16) | -0.6 | -0.5 (2000-17) | -0.5 | ||
Breast | Female | All Races | -2.3* (2000-04) 0.3* (2004-16) | 0.3* | -2.4* (2000-04) 0.3* (2004-17) | 0.3* |
White | -2.5* (2000-04) 0.2 (2004-16) | 0.2 | -2.6* (2000-04) 0.2 (2004-17) | 0.2 | ||
Black | 0.6* (2000-16) | 0.6* | 0.6* (2000-17) | 0.6* | ||
Cervix | Female | All Races | -3.8* (2000-03) -1.5* (2003-13) 1.2 (2013-16) | 0.5 | -4.0* (2000-03) -1.4* (2003-13) 0.7 (2013-17) | 0.7 |
White | -4.8* (2000-03) -0.1 (2003-08) -2.2* (2008-13) 2.8* (2013-16) | 1.5* | -4.7* (2000-03) -0.6* (2003-17) | -0.6* | ||
Black | -2.7* (2000-16) | -2.7* | -2.6* (2000-17) | -2.6* | ||
Colon and Rectum | Male | All Races | -2.5* (2000-08) -4.1* (2008-11) -1.4* (2011-16) | -1.4* | -2.6* (2000-17) | -2.6* |
White | -3.0* (2000-12) -1.4 (2012-16) | -1.4 | -3.0* (2000-12) -1.5* (2012-17) | -1.5* | ||
Black | -2.5* (2000-16) | -2.5* | -2.5* (2000-17) | -2.5* | ||
Female | All Races | -2.1* (2000-08) -3.0* (2008-13) -0.2 (2013-16) | -0.9 | -2.2* (2000-17) | -2.2* | |
White | -2.4* (2000-13) -0.2 (2013-16) | -0.8 | -2.4* (2000-13) -0.5 (2013-17) | -0.5 | ||
Black | -1.3* (2000-06) -2.9* (2006-16) | -2.9* | -2.4* (2000-17) | -2.4* | ||
Corpus and Uterus NOS | Female | All Races | -1.5 (2000-03) 1.5* (2003-16) | 1.5* | -1.7 (2000-03) 1.5* (2003-17) | 1.5* |
White | -1.9 (2000-03) 1.3* (2003-16) | 1.3* | -2.0 (2000-03) 1.3* (2003-17) | 1.3* | ||
Black | 2.4* (2000-16) | 2.4* | 2.3* (2000-17) | 2.3* | ||
Esophagus | Male | All Races | -1.0* (2000-16) | -1.0* | -0.9* (2000-17) | -0.9* |
White | -0.4* (2000-16) | -0.4* | -0.3* (2000-17) | -0.3* | ||
Black | -4.7* (2000-16) | -4.7* | -4.6* (2000-17) | -4.6* | ||
Female | All Races | -1.6* (2000-16) | -1.6* | -1.6* (2000-17) | -1.6* | |
White | -1.0* (2000-16) | -1.0* | -1.0* (2000-17) | -1.0* | ||
Black | -3.9* (2000-16) | -3.9* | -3.8* (2000-17) | -3.8* | ||
Hodgkin Lymphoma | Male | All Races | 1.0 (2000-07) -1.5* (2007-16) | -1.5* | 1.1 (2000-07) -1.7* (2007-17) | -1.7* |
White | 1.1 (2000-07) -1.7* (2007-16) | -1.7* | 1.1 (2000-07) -1.9* (2007-17) | -1.9* | ||
Black | 0.3 (2000-16) | 0.3 | 0.0 (2000-17) | 0.0 | ||
Female | All Races | 2.3 (2000-05) -1.6* (2005-16) | -1.6* | 2.9 (2000-04) -1.3* (2004-17) | -1.3* | |
White | 2.1 (2000-05) -1.7* (2005-16) | -1.7* | 1.0 (2000-07) -1.8* (2007-17) | -1.8* | ||
Black | 0.3 (2000-16) | 0.3 | 0.2 (2000-17) | 0.2 | ||
Kidney and Renal Pelvis | Male | All Races | 3.0* (2000-08) 0.5* (2008-16) | 0.5* | 2.4* (2000-05) 4.3* (2005-08) -0.8 (2008-11) 1.1* (2011-17) | 1.1* |
White | 2.9* (2000-08) 0.6* (2008-16) | 0.6* | 2.9* (2000-08) 0.6* (2008-17) | 0.6* | ||
Black | 3.4* (2000-08) 0.4 (2008-16) | 0.4 | 3.2* (2000-09) 0.0 (2009-17) | 0.0 | ||
Female | All Races | 3.6* (2000-07) 0.5 (2007-16) | 0.5 | 3.5* (2000-07) 0.7* (2007-17) | 0.7* | |
White | 4.1* (2000-06) 0.7* (2006-16) | 0.7* | 4.0* (2000-06) 0.9* (2006-17) | 0.9* | ||
Black | 4.0* (2000-08) 0.8 (2008-16) | 0.8 | 1.2 (2000-05) 7.9 (2005-08) 0.2 (2008-17) | 0.2 | ||
Larynx | Male | All Races | -4.4* (2000-03) -1.7* (2003-10) -3.3* (2010-16) | -3.3* | -4.5* (2000-03) -1.8* (2003-11) -3.6* (2011-17) | -3.6* |
White | -2.3* (2000-16) | -2.3* | -4.2* (2000-03) -1.5* (2003-11) -3.7* (2011-17) | -3.7* | ||
Black | -3.3* (2000-16) | -3.3* | -3.2* (2000-17) | -3.2* | ||
Female | All Races | -2.1* (2000-16) | -2.1* | -2.2* (2000-17) | -2.2* | |
White | -2.0* (2000-16) | -2.0* | -2.1* (2000-17) | -2.1* | ||
Black | -1.7* (2000-16) | -1.7* | -1.8* (2000-17) | -1.8* | ||
Leukemia | Male | All Races | -0.5 (2000-07) 3.0 (2007-10) 0.4 (2010-16) | 0.4 | -0.7 (2000-06) 2.0* (2006-12) -0.1 (2012-17) | -0.1 |
White | -0.1 (2000-06) 1.4* (2006-16) | 1.4* | -0.4 (2000-06) 1.8* (2006-13) -0.2 (2013-17) | -0.2 | ||
Black | 0.5 (2000-16) | 0.5 | 0.5 (2000-17) | 0.5 | ||
Female | All Races | 0.8* (2000-16) | 0.8* | 0.9* (2000-17) | 0.9* | |
White | 1.0* (2000-16) | 1.0* | 1.0* (2000-17) | 1.0* | ||
Black | -1.2 (2000-07) 2.2* (2007-16) | 2.2* | -1.6* (2000-07) 3.3* (2007-12) 0.4 (2012-17) | 0.4 | ||
Liver and Intrahepatic Bile Duct | Male | All Races | 4.2* (2000-09) 2.3* (2009-14) -1.4 (2014-16) | 0.4 | 1.4 (2000-02) 4.8* (2002-08) 2.3* (2008-15) -2.1 (2015-17) | 0.1 |
White | -0.8 (2000-02) 7.6* (2002-05) 3.6* (2005-14) -2.2 (2014-16) | 0.6 | 0.2 (2000-02) 5.6* (2002-08) 3.1* (2008-14) -0.3 (2014-17) | 0.6 | ||
Black | 3.1* (2000-16) | 3.1* | 3.5* (2000-15) -5.2 (2015-17) | -0.9 | ||
Female | All Races | 2.9* (2000-16) | 2.9* | 3.0* (2000-17) | 3.0* | |
White | -0.3 (2000-03) 4.3* (2003-14) -0.8 (2014-16) | 1.7 | 0.2 (2000-03) 3.9* (2003-17) | 3.9* | ||
Black | 3.2* (2000-16) | 3.2* | 2.9* (2000-17) | 2.9* | ||
Lung and Bronchus | Male | All Races | -1.9* (2000-08) -3.1* (2008-16) | -3.1* | -2.0* (2000-08) -2.9* (2008-17) | -2.9* |
White | -1.8* (2000-08) -3.1* (2008-16) | -3.1* | -1.9* (2000-08) -2.9* (2008-17) | -2.9* | ||
Black | -2.8* (2000-16) | -2.8* | -2.8* (2000-17) | -2.8* | ||
Female | All Races | 0.1 (2000-07) -1.7* (2007-16) | -1.7* | 0.0 (2000-07) -1.5* (2007-17) | -1.5* | |
White | 0.1 (2000-07) -1.7* (2007-16) | -1.7* | 0.0 (2000-07) -1.5* (2007-17) | -1.5* | ||
Black | 1.2* (2000-06) -1.8* (2006-16) | -1.8* | 0.4 (2000-08) -1.9* (2008-17) | -1.9* | ||
Melanoma of the Skin | Male | All Races | 1.8* (2000-16) | 1.8* | 2.0* (2000-15) -2.4 (2015-17) | -0.2 |
White | 2.0* (2000-16) | 2.0* | 2.2* (2000-15) -2.8 (2015-17) | -0.3 | ||
Black | -0.9 (2000-16) | -0.9 | -0.5 (2000-17) | -0.5 | ||
Female | All Races | 1.4* (2000-16) | 1.4* | 1.4* (2000-17) | 1.4* | |
White | 1.7* (2000-16) | 1.7* | 3.0* (2000-05) 0.6 (2005-12) 4.6 (2012-15) -3.0 (2015-17) | 0.7 | ||
Black | 0.2 (2000-16) | 0.2 | -0.1 (2000-17) | -0.1 | ||
Myeloma | Male | All Races | 1.7* (2000-16) | 1.7* | 0.4 (2000-06) 2.8* (2006-12) 0.7 (2012-17) | 0.7 |
White | 1.6* (2000-16) | 1.6* | 1.6* (2000-17) | 1.6* | ||
Black | 1.6* (2000-16) | 1.6* | 1.6* (2000-17) | 1.6* | ||
Female | All Races | -0.1 (2000-06) 2.1* (2006-16) | 2.1* | -0.1 (2000-06) 2.0* (2006-17) | 2.0* | |
White | 0.0 (2000-07) 2.1* (2007-16) | 2.1* | -0.3 (2000-06) 2.0* (2006-17) | 2.0* | ||
Black | 2.0* (2000-16) | 2.0* | 2.0* (2000-17) | 2.0* | ||
Non-Hodgkin Lymphoma | Male | All Races | 0.8* (2000-07) -0.3* (2007-16) | -0.3* | 0.7* (2000-08) -0.4* (2008-17) | -0.4* |
White | 0.9* (2000-07) -0.3* (2007-16) | -0.3* | 0.9* (2000-07) -0.3* (2007-17) | -0.3* | ||
Black | 0.1 (2000-16) | 0.1 | 0.0 (2000-17) | 0.0 | ||
Female | All Races | 1.0 (2000-04) -0.4* (2004-16) | -0.4* | -0.1 (2000-17) | -0.1 | |
White | 0.6 (2000-06) -0.4* (2006-16) | -0.4* | -0.1 (2000-17) | -0.1 | ||
Black | 0.3 (2000-16) | 0.3 | 0.4* (2000-17) | 0.4* | ||
Oral Cavity and Pharynx | Male | All Races | -0.5 (2000-05) 1.0* (2005-16) | 1.0* | -0.5 (2000-05) 0.9* (2005-17) | 0.9* |
White | 1.1* (2000-16) | 1.1* | -0.2 (2000-05) 1.5* (2005-15) -1.5 (2015-17) | 0.0 | ||
Black | -4.4* (2000-05) -1.3* (2005-16) | -1.3* | -4.9* (2000-05) -1.0* (2005-17) | -1.0* | ||
Female | All Races | 0.1 (2000-16) | 0.1 | 0.2 (2000-17) | 0.2 | |
White | 0.4* (2000-16) | 0.4* | 0.4* (2000-17) | 0.4* | ||
Black | -0.9* (2000-16) | -0.9* | -1.0* (2000-17) | -1.0* | ||
Ovary | Female | All Races | -1.5* (2000-16) | -1.5* | -1.6* (2000-17) | -1.6* |
White | -1.6* (2000-16) | -1.6* | -1.7* (2000-17) | -1.7* | ||
Black | -0.8* (2000-16) | -0.8* | -0.8* (2000-17) | -0.8* | ||
Pancreas | Male | All Races | 0.8* (2000-16) | 0.8* | 0.9* (2000-17) | 0.9* |
White | 1.0* (2000-16) | 1.0* | 1.0* (2000-17) | 1.0* | ||
Black | 0.2 (2000-16) | 0.2 | 0.3 (2000-17) | 0.3 | ||
Female | All Races | 0.8* (2000-16) | 0.8* | 0.9* (2000-17) | 0.9* | |
White | 1.0* (2000-16) | 1.0* | 1.0* (2000-17) | 1.0* | ||
Black | 0.1 (2000-16) | 0.1 | 0.2 (2000-17) | 0.2 | ||
Prostate | Male | All Races | -1.8* (2000-10) -9.0* (2010-14) 3.9 (2014-16) | -2.7 | -1.8* (2000-10) -8.8* (2010-14) 3.5 (2014-17) | 0.3 |
White | -1.9* (2000-10) -9.4* (2010-14) 4.0 (2014-16) | -2.9 | -1.9* (2000-10) -9.2* (2010-14) 3.3 (2014-17) | 0.0 | ||
Black | -2.1* (2000-11) -9.6* (2011-14) 4.0 (2014-16) | -3.0 | -2.1* (2000-11) -9.2 (2011-14) 2.9 (2014-17) | -0.2 | ||
Stomach | Male | All Races | -1.4* (2000-16) | -1.4* | -1.4* (2000-17) | -1.4* |
White | -1.1* (2000-16) | -1.1* | -1.1* (2000-17) | -1.1* | ||
Black | -0.8 (2000-08) -8.1 (2008-11) 2.6 (2011-14) -5.7 (2014-16) | -1.6 | -2.3* (2000-17) | -2.3* | ||
Female | All Races | -0.5* (2000-16) | -0.5* | -0.5* (2000-17) | -0.5* | |
White | -0.2 (2000-16) | -0.2 | -0.2 (2000-17) | -0.2 | ||
Black | -1.7* (2000-16) | -1.7* | -1.8* (2000-17) | -1.8* | ||
Testis | Male | All Races | 0.8* (2000-16) | 0.8* | 0.8* (2000-17) | 0.8* |
White | 0.8* (2000-16) | 0.8* | 0.8* (2000-17) | 0.8* | ||
Black | 1.2 (2000-16) | 1.2 | 1.1 (2000-17) | 1.1 | ||
Thyroid | Male | All Races | 5.7* (2000-11) 1.0 (2011-16) | 1.0 | 6.2* (2000-09) 2.7* (2009-15) -3.7 (2015-17) | -0.5 |
White | 6.1* (2000-10) 1.5* (2010-16) | 1.5* | 6.3* (2000-09) 2.6* (2009-15) -3.3 (2015-17) | -0.4 | ||
Black | 3.6* (2000-16) | 3.6* | 4.4* (2000-14) -5.7 (2014-17) | -3.3 | ||
Female | All Races | 6.9* (2000-09) 2.4* (2009-14) -1.8 (2014-16) | 0.3 | 6.3* (2000-06) 8.0* (2006-09) 1.9* (2009-15) -5.4* (2015-17) | -1.8* | |
White | 7.1* (2000-09) 2.3* (2009-14) -1.6 (2014-16) | 0.3 | 7.1* (2000-09) 2.1* (2009-15) -5.6* (2015-17) | -1.9* | ||
Black | 5.7* (2000-14) -4.5 (2014-16) | 0.5 | 5.8* (2000-14) -6.0* (2014-17) | -3.2 | ||
Urinary Bladder | Male | All Races | 0.0 (2000-07) -1.5* (2007-16) | -1.5* | 0.0 (2000-07) -1.4* (2007-17) | -1.4* |
White | 0.0 (2000-07) -1.4* (2007-16) | -1.4* | 0.0 (2000-07) -1.3* (2007-17) | -1.3* | ||
Black | -0.1 (2000-16) | -0.1 | -0.2 (2000-17) | -0.2 | ||
Female | All Races | -1.0* (2000-16) | -1.0* | -1.1* (2000-17) | -1.1* | |
White | -0.9* (2000-16) | -0.9* | -1.0* (2000-17) | -1.0* | ||
Black | -0.7* (2000-16) | -0.7* | -0.8* (2000-17) | -0.8* | ||
* The APC/AAPC is significantly different from zero (p<.05). |